Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 20,881 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Withdrawn Phase 2 Interventional

Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma

NCT00992173
View directory record Official record
Conditions
Neuroblastoma
Interventions
Ultratrace Iobenguane I 131
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 21, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

NCT03907241
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
Octanorm 16.5%
Drug
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Irvine, California • San Diego, California • Centennial, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 21, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas

NCT03429166
View directory record Official record
Conditions
PTSD
Interventions
Skills Training in Affective and Interpersonal Regulation, Present Centered Therapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Palo Alto, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 21, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence

NCT00915005
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Photon Therapy, Proton Therapy, Paclitaxel, Carboplatin
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 21, 2026, 6:45 PM EDT
Active, not recruiting Phase 3 Interventional

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

NCT02685605
View directory record Official record
Conditions
Glioblastoma
Interventions
Standard surgery, Intraoperative radiotherapy, Radiochemotherapy, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
Universitätsmedizin Mannheim
Other
Eligibility
18 Years to 80 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Maywood, Illinois • Lake Success, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 21, 2026, 6:45 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy

NCT03362502
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
PF-06939926
Genetic
Lead sponsor
Pfizer
Industry
Eligibility
4 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
22
States / cities
Los Angeles, California • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Endostatin in Treating Patients With Advanced Solid Tumors

NCT00004229
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant human endostatin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 21, 2026, 6:45 PM EDT
Recruiting Phase 3 Interventional

Extension Study for the Port Delivery System With Ranibizumab (Portal)

NCT03683251
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant with Ranibizumab 100 mg/mL
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
81
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 6:45 PM EDT
Terminated Phase 3 Interventional Results available

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

NCT02548351
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Obeticholic Acid, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 21, 2026, 6:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparing the Stanford Letter Project Form to Traditional Advance Directives

NCT02799537
View directory record Official record
Conditions
Advance Directives, Palliative Care
Interventions
Randomized clinical study
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 21, 2026, 6:45 PM EDT
Completed Not applicable Interventional

Chatbot for Depression, Anxiety, and Eating Disorders

NCT06013137
View directory record Official record
Conditions
Depression, Anxiety, Eating Disorders
Interventions
Therabot
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 21, 2026, 6:45 PM EDT
Withdrawn Phase 2 Interventional

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

NCT00005645
View directory record Official record
Conditions
Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
ILX-295501
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
8
States / cities
Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 21, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

NCT01510327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loveland, Colorado • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 21, 2026, 6:45 PM EDT
Withdrawn Not applicable Interventional

Coronary Calcium Scoring Versus Standard Care for Emergency Department Chest Pain Patients

NCT02828761
View directory record Official record
Conditions
Chest Pain
Interventions
Coronary Calcium Scoring, Standard Care
Device · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 21, 2026, 6:45 PM EDT
Recruiting Phase 2 Interventional

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

NCT07489066
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
Interventions
PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
15
States / cities
Huntsville, Alabama • Stanford, California • Athens, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 6:45 PM EDT
Withdrawn Phase 2 Interventional

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

NCT00006669
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, sargramostim, EPOCH regimen, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 21, 2026, 6:45 PM EDT
Not yet recruiting Phase 1 Interventional

Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial

NCT07590583
View directory record Official record
Conditions
Advanced Hormone Receptor-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Hormone Receptor-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Positron Emission Tomography, Treatment Planning, Treatment Regimen
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 21, 2026, 6:45 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441
View directory record Official record
Conditions
Resectable Non-small Cell Lung Cancer
Interventions
Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
8
States / cities
Clermont, Florida • Chicago, Illinois • Westwood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 6:45 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Efficacy of Manual Therapy to Improve Quality of Life and Decrease Pain in Subjects With Endometriosis

NCT03118154
View directory record Official record
Conditions
Endometriosis, Pelvic Pain, Dysmenorrhea
Interventions
Manual Physical Therapy
Other
Lead sponsor
Clear Passage Therapies, Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 21, 2026, 6:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nanopulse Efficacy Study for the Treatment of Common Warts

NCT02650466
View directory record Official record
Conditions
Common Warts
Interventions
Nanopulse System
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 21, 2026, 6:45 PM EDT
Recruiting Phase 4 Interventional

A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia

NCT07542756
View directory record Official record
Conditions
Insomnia, Insomnia Disorder, Chronic Insomnia, Chronic Insomnia Disorder
Interventions
Sleep Hygiene Education, Melatonin IR, 3 mg, Melatonin IR, 5 mg, Diphenhydramine, 25 mg, Diphenhydramine, 50 mg, Doxepin, 3 mg, Doxepin, 6 mg, Trazodone, 50 mg, Trazodone, 100 mg, Placebo, Zolpidem, 5 mg, Zolpidem, 10 mg
Other · Dietary Supplement · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of KPL-914 in Recurrent Pericarditis

NCT03980522
View directory record Official record
Conditions
Recurrent Pericarditis
Interventions
KPL-914
Drug
Lead sponsor
Kiniksa Pharmaceuticals (UK), Ltd.
Industry
Eligibility
6 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Washington D.C., District of Columbia • DeLand, Florida • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 21, 2026, 6:45 PM EDT
Terminated Not applicable Interventional

Comparison of Training Load With/Out Blood Flow Restriction Training in Rheumatoid Populations

NCT04309227
View directory record Official record
Conditions
Rheumatoid Arthritis, Myositis, Osteoarthritis, Weakness, Muscle
Interventions
Strength Training
Other
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 21, 2026, 6:45 PM EDT
Completed Not applicable Interventional

Effectiveness of Acupuncture for Depressed Patients Not Taking Antidepressant Medications

NCT01634022
View directory record Official record
Conditions
Depression
Interventions
Acupuncture
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Oct 21, 2026, 6:45 PM EDT